Britain’s biotech firms now have a code of conduct designed to prevent them
from overhyping the progress of experimental drugs. Published this week by the
BioIndustry Association (BIA), the code was drafted in the wake of a damaging
scandal last year
(This Week, 4 July 1998, p 20).
From now on, companies must
have their scientific and clinical progress audited by external experts. Failure
to comply could mean expulsion from the BIA.
More from Â鶹´«Ã½
Explore the latest news, articles and features
Popular articles
Trending Â鶹´«Ã½ articles
1
Are Neanderthals descendants of modern humans?
2
Why is it so hard to change your mind?
3
The biggest threat to Chernobyl is no longer radiation
4
Our dreams become more emotive and symbolic as we approach death
5
Electric vehicle owners could earn thousands by supporting power grid
6
Surprising male G-spot found in most detailed study of the penis yet
7
From autism to migraines, birth order may have wide-reaching effects
8
Collapse of key ocean current may release billions of tonnes of carbon
9
How worried should you be about an AI apocalypse?
10
The man who crawls into the perilous heart of the Chernobyl reactor
